Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-centre, Single-arm, Prospective Study to Assess Efficacy and Safety of Neoadjuvant Hormone Therapy Using Zoladex (Goserelin) and Casodex (Bicalutamide) in Patients With Advanced Prostate Cancer Undergoing Radical Prostatectomy.

NCT03971110 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT03971110
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03971110 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-centre, Single-arm, Prospective Study to Assess Efficacy and Safety of Neoadjuvant Hormone Therapy Using Zoladex (Goserelin) and Casodex (Bicalutamide) in Patients With Advanced Prostate Cancer Undergoing Radical Prostatectomy.
Lead sponsor
AstraZeneca
Phase
Phase 4
Overall status
Terminated
Start date
January 28, 2021
Completion date
November 9, 2022
Enrollment
9 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

advanced prostate cancer